OTCMKTS:RLMD
Relmada Therapeutics, Inc. Stock Company Profile
$3.83
+0.130 (+3.51%)
At Close: Apr 26, 2024
Information
2222 Ponce de Leon Boulevard, Floor 3
Coral Gables FL 33134
786 629 1376
www.relmada.com
Industry: Biotechnology
Sector: Healthcare
Description
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
